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Venoms of snakes, scorpions, spiders, insects, sea anemones,
and cone snails are complex mixtures of mostly peptides and
small proteins that have evolved for prey capture and/or
defense. These deadly animals have long fascinated scientists
and the public. Early studies isolated lethal components in the
search for cures and understanding of their mechanisms of
action. Ion channels have emerged as targets for many venom
peptides, providing researchers highly selective and potent
molecular probes that have proved invaluable in unraveling ion
channel structure and function. This minireview highlights
molecular details of their toxin-receptor interactions and
opportunities for development of peptide therapeutics.
Ion channels are a diverse class of membrane proteins that
play critical roles in cellular physiology, underlying such essen-
tial processes as neuronal signaling andmuscle contractility (1).
Given these key functions, it is not surprising many toxins have
evolved to block or activate ion channels, often with exquisite
potency and selectivity. This is most evident among venoms of
snakes, spiders, scorpions, insects, cone snails, and sea anemo-
nes used for prey capture and predator defense. Their venoms
provide a virtually untapped reservoir of millions of bioactive
peptides with highly diverse sequences and structures, includ-
ing many that target ion channels of clinical importance (2).
Venom peptides typically act on peripheral targets after injec-
tion through a specialized envenomation apparatus such as
fangs, stings, harpoons, and nematocysts. Their high potency
and target specificity for membrane proteins have been
achieved through the evolution of structurally rigid peptide
folds with well defined functional faces.
Key ion channel targets of venom peptides include voltage-
gated potassium, sodium, and calcium channels and the ligand-
gated nicotinic acetylcholine receptors, where toxins acting at
different binding sites have evolved across multiple phyla. In
addition, a smaller set of venom peptides have evolved to target
the NMDA3 receptor and ASICs. This minireview examines a
selection of venompeptides used to probe these ion channels at
the functional and structural level.
Potassium Channel Toxins
K channels are four-domainmembrane proteins that selec-
tively transport K ions across the cell membrane, where they
play a key role in regulating cell excitability (3) and non-excit-
able cell physiology. K channels comprise two conserved
transmembrane segments in each domain, which form the core
of the ion-conducting pore and support an extracellular linker
that folds back into the channel to form the ion selectivity filter.
Apart from these conserved elements, the topology of K chan-
nel subtypes varies greatly, with each domain comprising two,
four, or six transmembrane segments. Since the groundbreak-
ing study of the MacKinnon group in 1998 (4), multiple crystal
structures of K channels have expanded our understanding of
ion selectivity and gating mechanisms that regulate passage of
ions due to changes in membrane potential.
The diversity of K channels is considerable, with75 genes
identified in mammalian genomes (5), and includes voltage-
activated K channels (Kv), Ca2-activated K channels (KCa),
inward rectifier K channels (Kir), and two-pore K channels
(K2P). Thankfully, the venoms of snakes, cone snails, spiders,
anemones, and particularly scorpions have provided research-
ers with potent subtype-selective pharmacological tools, in-
cluding several with therapeutic potential (2). Many of these
peptides possess a conserved functional dyad, comprising a Lys
residue near a Tyr, Phe, or Leu, indicative of convergent evolu-
tion among many (6) but not all (7) K channel toxins.
Scorpion—Some 25 years ago, noxiustoxin, isolated from
venom ofCentruroides noxius, was the first identified K chan-
nel-blocking peptide (8). Since then,120 KTxs ranging from
23 to 64 aa have been sequenced (9). Based on sequence identity
and cysteine pairing, scorpion toxins are classified into three
subfamilies, the -, -, and -KTxs. Most KTx structures
exhibit a characteristic fold comprising short elements of sec-
ondary structure (one-helix and two or three-strands). This
suggests a conserved binding mode. However, KTxs have
evolved to use different faces of their structure to interact with
different K channels (9). For instance, charybdotoxin
(KTx1.1) and agitoxin 2 (KTx3.2) interact with the Shaker (or
Kv1) channel using residues protruding from the -strand
motif (10, 11), whereas BmPO5 (KTx5.3) binds to the KCa2.2
channel using residues in the -helical motif (12).
After the release of the three-dimensional coordinates of the
K channel crystal structure, several groupsmodeled the inter-
action of scorpion toxins with their target (12, 13). These mod-
els generally agreed with mutagenesis data and helped predict
interacting pairs of residues. However, the recent solid-state
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NMRstructure revealed significant rearrangements and/or sta-
bilization of specific conformations in both kaliotoxin and a
chimeric K channel that occurred upon toxin binding (14),
although the critical Lys27 physically occludes the pore as pre-
dicted. This mode of binding appears to be shared with some
anemone and cone snail K channel toxins (Fig. 1A).
Sea Anemone—Sea anemones also have yielded a diversity of
K channel peptide inhibitors classified into three main types
(15). Type 1 toxins comprise 35–37 aa constrained by three
disulfide bonds andmostly target Kv1 (Shaker) channels. Struc-
ture-activity studies reveal an SKY motif in both ShK (Ser20,
Lys22, and Tyr23) and BgK (Ser23, Lys25, and Tyr26) toxins that
are critical for binding. This SKY motif is absolutely conserved
in all type 1 toxins, and docking studies based on double-mu-
tant cycle analysis reveal a plausible mode of interaction (Fig.
1A) (16). Recently, a stable and Kv1.3-selective analog of ShK
demonstrated potential in the treatment of autoimmune dis-
eases such as multiple sclerosis and rheumatoid arthritis (17).
Type 2 toxins, comprising 58–59 aa and three disulfide bonds,
also block Kv1 channels but not as potently as type 1 toxins.
Type 2 toxins belong to the Kunitz-type family of peptides and
have dual K channel and protease inhibitory activity (18).
Type 3 toxins comprise 42–43 aa and three disulfide bonds.
BDS-I and BDS-II are selective inhibitors of the Kv3.4 channel,
whereas APETx1 is selective for the HERG (human ether-a-go-
go-related gene) K channel. Presently, no docking simulations
have been reported for these toxins.
Cone Snail—Several toxins isolated from venom of Conus
species affect K channels. The first discovered was -cono-
toxin PVIIA (27 aa) from the venomofConus purpurascens and
shown to inhibit the Shaker K channel (19) through the func-
tional dyad comprising Lys7 and Phe9 plus Lys25 (20). A model
of the -conotoxin PVIIA-Shaker K channel complex showed
a reasonable correlation with experimental data (Fig. 1A) (21).
Interestingly, -PVIIA can reduce infarct size in rabbit hearts
when administered at reperfusion (22). In contrast, the struc-
turally unrelated M-RIIIK has a distinct binding mode (Fig.
1A) that is apparently not based on a functional dyad (23). A
number of conopeptides with unrelated structures have been
reported recently, including conkunitzin-S1, which is structur-
ally homologous to snake dendrotoxins, and pl14a from Conus
planorbis, which was docked onto Kv1.6 (Fig. 1A).
Snake—Isolated 20 years ago from African snakes (Den-
droaspis sp.), dendrotoxins have proved remarkable tools to
study K channel structure and function. These peptides com-
prise 57–60 aa and three disulfide bonds that stabilize a
“Kunitz-type toxin” fold. Initially, the high affinity binding of
dendrotoxins was exploited to isolate a K channel protein
(24). Later, structure-activity studies of - and -dendrotoxins
revealed the importance of the functional dyad, and several
models of the interaction of dendrotoxins with K channels
have been proposed (25, 26). Other snake toxins also affect
K channel activity, including -bungarotoxin, sarafotoxins,
and the much larger natrin. Recently, natrin was docked
onto Kv1.3 through a small contact surface (Fig. 1A), sug-
gesting truncated forms of natrin may yield novel channel
inhibitors.
Spider—Spider venoms contain “gating modifier peptides”
that act at K channels. Hanatoxin, 35-aa three-disulfide bond
peptide, binds to the S3b helix of the voltage sensor paddle
motif of the K channel (27). Other spider toxins targeting the
K channel voltage sensor include guangxitoxin (GxTx1E),
which has high affinity for Kv2.1; stromatoxin (ScTx1) and het-
eroscodratoxins (HmTx1,2), which target Kv2 and Kv4 chan-
nels; heteropodatoxins (HpTx1–3), phrixotoxins (PaTx1,2),
and TLTx1–3, which preferentially inhibit Kv4 channels;
PhTx3-1, which inhibits the outward rectifier A-type K chan-
nel; and the Kunitz-type huwentoxin XI, which inhibits trypsin
and weakly Kv1.1. Interestingly, the bacterial Kv channel iso-
lated from VsTx1 (28) may allow a spider toxin-K channel
co-crystal structure to be solved.
Sodium Channel Toxins
Voltage-sensitive Na channels are four-domain membrane
proteins essential for electrical signaling in cells. Nine sodium
channel subtypes (Nav1–9) have been cloned (1), including
some selectively expressed in pain pathways such as Nav1.8. A
number of Nav mutations that underlie genetic diseases,
including epilepsy and migraines, have been identified.
Seven toxin-binding sites have been described for Nav chan-
nels (sites 1–7) that enhance or inhibit passage ofNa ions. The
first Na channel inhibitor described was TTX, a poison pro-
duced by bacteria and accumulated through the diet of puffer
fish. TTX binds in themouth of the ion-conducting pore at low
nM concentrations at TTX-sensitive (Nav1.1–1.4, Nav1.6, and
Nav1.7) and M concentrations at TTX-resistant (Nav1.5,
Nav1.8, and Nav1.9) Na channels. TTX and related saxitoxins
FIGURE 1. Venom peptides in complex with K and Na channels. Inter-
acting residues are shown in stick representation, with toxins in red and the
two apposing receptor subunits in blue and green. Except for the kaliotoxin-
KcsA-Kv1.3 complex (14), derived from solid-state NMR data, all other toxin-
receptor complexes are theoretical models derived from computational sim-
ulations. A, scorpion, anemone, and cone snail toxin complexes with their
respective K channels. For clarity, only the turret selectivity filter of the chan-
nel is shown for BgK-Kv1.1 (16), PVIIA-Shaker (21), RIIIK-TSha1 (87), pl14a-Kv1.6
(88), and natrin-Kv1.3 (89) complexes. B, cone snail and scorpion toxin com-
plexeswithNa channels.-ConotoxinGIIIA (Ctx-GIIIA) is showndockedonto
the selectivity filter of a Nav1.4 model (90), and scorpion toxin CssIV is shown
interacting with the voltage sensor of Nav1.2 (33).
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produced by dinoflagellates define site 1 in the pore of the
-subunit of Na channels. Other non-peptidic Na channel
poisons include the site 2 activating alkaloid toxins from frogs
and plants (batrachotoxin and veratridine), the site 5 activating
dinoflagellate polyether toxins (brevetoxins and ciguatoxins)
responsible for neurological shellfish poisoning and ciguatera,
and the site 7 activating insect-selective plant pyrethroids. In
contrast, venom peptides act at sites 1, 3, 4, and 6.
Scorpion—The long chain Na channel toxins found in scor-
pion venom comprise 64 aa with four disulfide bonds that
constrain a highly structured globular -fold. Two classes
of activating scorpion toxins have been characterized. The
scorpion -toxins slow inactivation, and the scorpion -toxins
shift the voltage dependence of activation and first defined sites
3 and 4, respectively (29). Rogers et al. (30) provided initial
details about receptor site 3 of scorpion -toxins. Combining
the natural variation in peptide sequence withmutational stud-
ies is now revealing specific regions important for scorpion -
and-toxins. For instance, details about the interaction of scor-
pion -toxins with receptor site 4 have been uncovered by
mutagenesis and double-mutant cycle analysis (31, 32), and a
model depicting howa scorpion-toxinmight interactwith the
voltage sensor of Nav1.2 has been proposed (Fig. 1B) (33).
Cone Snail—The -conotoxins were among the first peptide
inhibitors of Na channels identified. These small polar
16–25-aa peptides possess a tightly folded globular structure
stabilized by three disulfide bonds. NMR solution structures of
SIIIA, TIIIA, PIIIA,GIIIA,GIIIB, KIIIA, and SmIIIA reveal they
all have a similar fold except SIIIA, which has a much shorter
loop 1 and an helical motif between residues 11 and 16 (34) not
seen in the larger -conotoxins like TIIIA (35). All -conotox-
ins possess either an exposed Arg or Lys in loop 2 that is impor-
tant for high affinity interactions with the Na channel. How-
ever, its role is less critical for SIIIA and KIIIA, where the
pharmacophore has shifted into the helical region of the pep-
tide. -Conotoxins preferentially target Nav1.4 and Nav1.2 and
have weak or no detectable affinity at the validated therapeutic
targets Nav1.7 and Nav1.8. A docking model depicting how
-conotoxin GIIIA might plug the selectivity filter of the mus-
cle Na channel (Nav1.4) is shown in Fig. 1B. This model high-
lights the critical role of Arg13 in the high affinity interaction
with Nav1.4. As our understanding of the architecture of the
outer vestibule of theNa channel develops, conotoxins able to
block specific Na channel subtypes may be rationally
designed.
Cone snail venoms contain two other classes of hydrophobic
Na channel toxins, the O-conotoxins MrVIA and MrVIB
isolated from Conus marmoreus and the more diverse -cono-
toxins isolated frommollusc- and fish-hunting cone snails. The
O-conotoxins are 31-aa peptides that preferentially block
(15-fold selective) Nav1.8 and Nav1.4 over other voltage-
gated Na channel subtypes by interfering with the domain II
voltage sensor of the Na channel (36). In rats, intrathecal
administration of MrVIA was analgesic at doses that produced
no local anesthetic-like effects on movement or coordination,
revealing that chemical dissection of Nav1.8 has therapeutic
potential (37). MrVIB was also analgesic after peripheral
administration, but effects onNav1.4 complicate interpretation
of behavioral data. Structure-activity relationships of
O-conotoxins are hampered by difficulties in folding and
purifying these peptides efficiently.
The 27–31-residue -conotoxins have structures reminis-
cent of the O-conotoxins but inhibit Na channel inactiva-
tion like the scorpion -toxins (38). The -conotoxins include
TxVIA, a selective activator of mollusc Na channels, and
EVIA, a selective activator of mammalian neuronal Na chan-
nels (39). A cladistics approach is starting to reveal residues that
contribute to their structure-activity at Na channels (40).
ConoServer provides an online database of conotoxins and
conopeptides (41).
Spider—Tx1 from the South American armed spider Pho-
neutria nigriventer was recently found to inhibit -conotoxin
GIIIB but not TTX binding (42), revealing that pore block can
be achieved at multiple overlapping positions in the mouth of
Na channels. Perhaps the most interesting spider toxins are
gating modifiers that trap Na channels in non-conducting
state(s). These include protoxin II from the tarantula Thrix-
opelma pruriens, a 30-aa three-disulfide bond cysteine knot
peptide that traps the voltage sensor (43) and preferentially
inhibits the pain target Nav1.7 (44). The slightly larger hainan-
toxins andhuwentoxins from theChinese bird spiderOrnithoc-
tonus spp. are also gating modifiers (45). Interestingly, the site
of action of huwentoxin IV overlaps site 4 but traps the voltage
sensor of domain II in the inward configuration in contrast with
scorpion -toxins, which trap the voltage sensor in an outward
configuration (46). Another well studied toxin,Magi 5 from the
hexathelid spider Macrothele gigas, is less than half the size of
the scorpion -toxins (29 residues) that act at site 4, making it a
valuable tool for structure-function relationship studies (47).
Magi 5 binds to receptor site 4 onmammalianNav1.2 and com-
petes with scorpion-toxins such as CssIV. A complete alanine
scan revealed nine mutants lost biological activity, with an NMR
structure attributing these residues todistinctpolar andnon-polar
surfaces (48). Thus, spider toxins provide opportunities for devel-
opment of subtype-specific Na channel inhibitors.
Not surprisingly given their prey, spiders produce an array of
insect-active Na channel toxins, including the 40-aa four-
disulfide bond -atracotoxins (renamed -hexatoxins), which
activate Na channels through site 3 by slowing inactivation.
Interestingly, recent structural comparisons reveal key residues
important for -hexatoxin activity appear to be distributed in a
similar manner to that seen in the distantly related scorpion
-toxins (49). Given their potent ability to kill insects, spider
toxins acting at Na channels also have potential as selective
insecticides in agricultural settings (50). ArachnoServer pro-
vides a comprehensive online database of spider toxins (51).
Calcium Channel Toxins
VGCCs are structurally related to voltage-gated Na chan-
nels. These channels selectively gate the influx of Ca ions
required for muscle contraction and neurotransmitter release.
In recent years, much has been discovered about the nature of
these channels, which have been classified as L-, N-, P-, Q-, T-,
and R-types according to their electrophysiological and phar-
macological characteristics. Given their diversity and overlap-
ping roles in neurotransmitter release, subtype-selective inhib-
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itors are required to determine their relative roles in normal
and disease processes. Unfortunately, lack of appropriate crys-
tal structure templates for mammalian calcium channels has
limited attempts to generate predictive homology models.
Cone Snail—-Conotoxins from fish-hunting cone snails are
among the most potent ichthyotoxins. However, it is their
selectivity for specific mammalian Ca channel subtypes that
has been pivotal in determining the physiological role of spe-
cific neuronal Ca channels, especially Cav2.2, where -cono-
toxins remain themost selective inhibitors known. The striking
ability of subnanomole doses of -conotoxin MVIIA or CVID
(52) to produce analgesia in rats for up to 24 h when delivered
intraspinally (intrathecally) helped identify the pivotal role of
N-type VGCCs in spinal pain transmission (53) and led to
development of a new class of pain therapeutic, with -cono-
toxin MVIIA (Prialt, Elan Corp.) approved for severe pain.
Unfortunately, MVIIA and CVID (AM336 or Leconitide) had
unwanted side effects at efficacious doses, possibly a result of
on-target effects at inhibitory spinal synapses and supraspinal
sites. -Conotoxin affinity for N-type Ca channels is reduced
upon coexpression with the auxiliary 2-subunit (54), which
might reduce the therapeutic window. Extensive structure-ac-
tivity studies allow the development of several pharmacophore
models for -conotoxins, but mimetics with high affinity
remain elusive.
Spider—The 48-aa four-disulfide bond-agatoxin IVA from
grass spider Agelenopsis aperta has become a reference inhibi-
tor used to define the role of Cav2.1 in cells and tissues (55). The
-agatoxins are gating modifier toxins that bind to S3 in
domain IV, a region that overlaps the binding site of other gat-
ing modifier toxins that act on K and Na channels, albeit
with different effects on channel gating (56). The 41-residue
three-disulfide bond SNX482 (-theraphotoxin Hg1a) from
the tarantulaHysterocrates gigas interacts with domains III and
IV to inhibit activation of VGCCs, including Cav2.3 (57). Ca
channel modulators from spiders also target insect Ca2 chan-
nels and may prove valuable in validating insecticidal Ca
channel targets.
Snake—Snake venoms contain a diversity of L-type Ca
channel inhibitors. Calciseptine, a 60-aa four-disulfide bond
peptide from black mamba Dendroaspis polylepsis polylepis
venom, selectively inhibits dihydropyridine-sensitive cardiac
L-type Ca2 channels but enhances L-type current in skeletal
muscle (58). Calcicludine from the green mamba Dendroaspis
angusticeps is a 60-residue three-disulfide bondpeptide, resem-
bling the dendrotoxins in structure, that blocks L-type Ca2
currents (59). Calcicludine causes only a partial block of current
through interactions across multiple domains to stabilize a low
conductance state of the channel in a manner reminiscent of
inhibition by dihydropyridines (60).
Nicotinic Acetylcholine Receptors
nAChRs are nonselective pentameric cation channels that
open in response to acetylcholine binding (61). The adult mus-
cle nAChR is the major neurotransmitter receptor at the neu-
romuscular junction and represents a target of choice for many
paralyzing toxins. From the 12 neuronal subunits known, few
form functional homopentamers (7 and 9), with most native
nAChRs having a subunit stoichiometry that comprises combi-
nations of different - and -subunits, e.g. 32 or 6423.
The soluble homopentameric AChBP, isolated by the Smit
group from Lymnaea, is structurally and functionally homolo-
gous to the ECD of nAChRs, albeit with low sequence identity
(25%) (61). The structure of AChBPwas first solved at atomic
resolution by Sixma and co-workers (62), revealing the archi-
tecture of the ACh-binding site in great detail. AChBP coordi-
nates have been used to model the ECD of ligand-gated ion
channels, especially nAChRs. Alkaloid poisons from plants
(nicotine, cytisine, anabaseine, methyllycaconitine, and
tubocurarine), poison dart frogs (epibatidine and analogs),
algae (anatoxin), and molluscs (neosurugatoxin) act at
nAChRs (63), with three toxins (nicotine, epibatidine, and
methyllycaconitine) co-crystallizedwithAChBP (supplemental
Fig. 2). Toxins within a structural family appear to bind in a
similar manner despite significant differences in primary
sequence.
Snake—The snake-neurotoxins (60–74 aa) are high affinity
nAChR ligands first used to help isolate and characterize the
nAChR. One of the most studied and widely used is -bunga-
rotoxin, purified in the 1960s from venom of the banded krait
Bungarus multicinctus and now co-crystallized with the rat
nAChR 1-subunit (64). This work represents the first atomic
resolution structure of the ECD of a mammalian ligand-gated
ion channel component, revealing a remarkable conservation
of architecture across species, with the ECD coordinates virtu-
ally superimposable with the structure of AChBP bound to the
related -cobratoxin (supplemental Fig. 2). It is evident both
-bungarotoxin and -cobratoxin utilize a common structural
motif comprising a short -helix to interact with the receptor,
confirming the large body of mutagenesis data.
Cone Snail—Conus species have evolved a broad range of
small -conotoxins that target nerve andmuscle nAChRs for
prey capture. A recent screen over the nAChR homolog
AChBP revealed the venom of all 30 species examined con-
tained significant nicotinic activity (65), indicating many
new ligands remain to be isolated. Indeed, subtype-selective
-conotoxins have significantly contributed to the charac-
terization of nAChRs both in vivo and in vitro, and some
even may have therapeutic applications. Three conotoxins
(-conotoxin ImI and variants of -conotoxins PnIA and
TxIA) have been co-crystallized with AChBP, revealing a
similar binding mode within the acetylcholine-binding
pocket (65–68). Common among the three structures is the
strong contribution of hydrophobic contacts between a con-
served proline and several hydrophobic residues of -cono-
toxins and residues in the aromatic cage of AChBP
(supplemental Fig. 2). Specific electrostatic interactions and
hydrogen bonds that are unique for each -conotoxin estab-
lish affinity and selectivity. For instance, the recently discov-
ered -conotoxin TxIA utilizes a strong electrostatic pairing
between Arg5 and AChBP Asp195 binding (65) that contrib-
utes to a tilt in its orientation within the acetylcholine-bind-
ing pocket. Based on these crystal structures, models for sev-
eral nAChR subtypes have been built and used as templates
to dock -conotoxins (69–72). Results from mutagenesis
experiments using these models were in agreement with the
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predictions, highlighting the potential of these docking
models to guide ligand design (73).
NMDA Receptors
NMDA receptors are tetrameric ligand-gated ion channels
with high Ca2 permeability that mediate fast excitatory neu-
rotransmission in the central nervous system. They are com-
posed mainly of two NR1 and two NR2 subunits and are impli-
cated in chronic and acute neurological disorders. Gouaux and
co-workers (74, 75) provided atomic resolution structures of
the NMDA extracellular binding domains bound to agonists,
partial agonists, and antagonists, opening the way to rational
development of NMDA receptor antagonists. To date, only
cone snails have yielded venom peptides targeting NMDA
receptors.
Conantokins are small peptides (17–22 aa) that selectively
and potently inhibit NMDA receptors. The first was isolated
from Conus geographus (76). Conantokins have potential as
analgesics (77) and anticonvulsants (78). Structure-activity
studies of conantokins (79) and a docking model suggesting
that conantokin G can fit into the agonist-binding cleft of the
NR2 subunit (supplemental Fig. 3) (80) should allow rational
design of mimetics.
Acid-sensing Ion Channels
ASICs are proton-gated cationic channels in the degenerin/
epithelial Na channel superfamily. ASICs play essential roles
in the detection and processing of sensory information. In
mammals, four genes code for ASICs, but alternative splicing
leads to six isoforms (ASIC1a, ASIC1b, ASIC2a, ASIC2b,
ASIC3, and ASIC4). Gouaux and co-workers (81) recently
determined the x-ray structure of an ASIC1 protein from
chicken, which revealed a chalice-like shaped trimer, with each
subunit composed of two transmembrane domains, a large
multidomain extracellular region, and a negatively charged
pocket at the interface of two adjacent subunits forming the
proton-binding site. To date, only a sea anemone and a spider
venom peptide have been shown to target ASICs, but only the
latter has been investigated in detail (82).
PcTx1, a 40-aa peptide from the SouthAmerican spiderPsal-
mopoeus cambridgei, potently and selectively inhibits homo-
mericASIC1a (IC50 1 nM) (83). PcTx1 reduces ischemic brain
injury in rat and mouse models of ischemia and reduces ther-
mal, mechanical, chemical, inflammatory, and neuropathic
pain behaviors in rodents (84). Docking of PcTx1 onto ASIC1
channel (85, 86) suggests it binds at the interface of two sub-
units, near the proton-binding site, consistent with experimen-
tal data.
Conclusions
Venom peptides have evolved to target ion channels using a
diversity of structures and modes of interaction. Given that
99% of venom peptides are pharmacologically uncharacter-
ized and that most known toxins target ion channels, venom
peptides remain a virtually untapped source of new probes for
research and leads to new therapeutics. With the increasing
availability of ion channel crystal structure templates, advanced
computational tools, and high throughput ion channel assays,
its is becoming viable to rationally designmodified venom pep-
tides for improved selectivity, distribution, and in vivo plasma
half-life, providing an alternative to traditional approaches to
ion channel drug discovery.
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